TENDER AND SUPPORT AGREEMENTTender and Support Agreement • December 12th, 2022 • Merck Sharp & Dohme LLC • Pharmaceutical preparations • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of November 19, 2022, is entered into by and among Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Parent”), M-Inspire Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and each of the persons set forth on Schedule A hereto (each, a “Stockholder” and together with Parent and Merger Sub, the “Parties” and each, a “Party”). All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).
AMENDED & RESTATED MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • December 12th, 2022 • Merck Sharp & Dohme LLC • Pharmaceutical preparations
This Amended & Restated Mutual Confidential Disclosure Agreement (this “Agreement”), effective as of the date of last signature below (the “Effective Date”), is entered into by and between Merck Sharp & Dohme LLC, successor to Merck Sharp & Dohme Corp., having an address of 126 East Lincoln Avenue, Rahway, New Jersey 07065 (hereinafter referred to as “Merck”) and Imago BioSciences, Inc., having an address of 303 Twin Dolphin Drive, 6th Floor, Redwood City, CA 94065 (hereinafter referred to as “Imago”) (each a “Party” and collectively, the “Parties”) and sets forth the terms and conditions under which the Parties will exchange certain proprietary and confidential information/data with respect to Imago’s LSD inhibitor programs, including bomedemstat and Merck’s interest therein (hereinafter collectively referred to as “Subject Matter”).
